FDA Reversal on AMT-130 Data Ignites 81% Surge and Analyst Upgrades
FDA accepts Phase I/II data for accelerated approval The FDA reversed its earlier stance and agreed that three-year data from the Phase I/II study of AMT-130 can be the main basis for a Biologics License Application. This removes a major regulatory hurdle, making approval much more likely and sending QURE up 81%.
This is the core new event that directly caused the stock's massive jump and changes the company's outlook.
BLA submission planned for Q3 2026 uniQure now plans to file for approval in the third quarter of 2026, a concrete near-term step. This gives investors a clear timeline and raises confidence that the therapy could reach the market sooner than expected.
It provides a specific catalyst date and shows the company is moving quickly toward commercialization.
Analyst upgrades and fair value increase Several Wall Street firms raised price targets, with Barclays and Cantor Fitzgerald upgrading to Overweight. The modelled fair value rose 35% to about $52.56, reflecting a potential $3 billion-plus peak sales opportunity for AMT-130.
Analyst actions and valuation changes show professional investors see significantly more upside after the FDA news.
Remaining execution risks and confirmatory study Despite the rally, Goldman Sachs kept a Neutral rating, noting that the FDA will still hold a meeting to discuss the design of a confirmatory study and that durability data are needed. These steps could delay or complicate final approval.
It provides a balanced view by highlighting that not all uncertainty is removed, which could cap further gains.